Condition (MeSH)
Creutzfeldt-Jakob Syndrome
ClinicalTrials.gov lists 14 trials for Creutzfeldt-Jakob Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
14 of the 14 trials are tagged with Creutzfeldt-Jakob Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Creutzfeldt-Jakob Syndrome trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 1 |
| 2017 | 1 |
| 2015 | 1 |
| 2010 | 1 |
| 2005 | 1 |
| 2004 | 1 |
| 2000 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Creutzfeldt-Jakob Syndrome trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 7 |
How many Creutzfeldt-Jakob Syndrome trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 5 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Creutzfeldt-Jakob Syndrome trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Medical Research Council | 1 |
| NHS Blood and Transplant | 1 |
| Regeneron Pharmaceuticals | 1 |
| Sheba Medical Center | 1 |
| Tel-Aviv Sourasky Medical Center | 1 |
Which drugs are being tested for Creutzfeldt-Jakob Syndrome? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Quinacrine | 2 |
| Efavirenz | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| No Interventions | 1 |
| PrP-siRNA | 1 |
| ALN-6457 | 1 |
| cAd3-EBO-S | 1 |
| cAd3-Marburg | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Creutzfeldt-Jakob Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death | 29 | 1 |
| Fall | 2 | 1 |
| Hemorrhage | 2 | 1 |
| Post-LP Dizziness | 2 | 1 |
| Post-LP headache | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Creutzfeldt-Jakob Syndrome? (29)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| White matter abnormalities in healthy E200K carriers may serve as an early biomarker for genetic Creutzfeldt-Jakob disease (gCJD). | Journal of neurology, neurosurgery, and psychiatry | 2025 | Yes |
| Personalized brain MRI revealed distinct functional and anatomical disruptions in Creutzfeldt-Jakob disease and Alzheimer's disease. | CNS neuroscience & therapeutics | 2024 | Yes |
| The natural history study of preclinical genetic Creutzfeldt-Jakob Disease (CJD): a prospective longitudinal study protocol. | BMC neurology | 2023 | Yes |
| Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice. | Acta neuropathologica communications | 2021 | Yes |
| In vivo [<sup>18</sup>F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. | Neurology | 2018 | Yes |
Showing 5 of 29 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.